Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-504 in Castration-Resistant Prostate Cancer
NCT00564928Phase 2Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Nov 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of retaspimycin in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Infinity Pharmaceuticals, Inc. Primary endpoint: Clinical response as determined by PSA and radiologic response rate at 12 weeks. Started Nov 2007; status: completed.
02
Drugs
retaspimycin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00564928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00564928.